A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 7450-7457

  Spohn, Gunther ^a   Guler, Reto ^b   Johansen, Pål ^c   Keller, Iris ^a   Jacobs, Muazzam ^b   Beck, Markus ^a   Rohner, Franziska ^a   Bauer, Monika ^a   Dietmeier, Klaus ^a   Kündig, Thomas M ^c   Jennings, Gary T ^a   Brombacher, Frank ^b   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ISONIAZID; MONOCLONAL ANTIBODY; RIFAMPICIN; SOLUBLE TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL ARTHRITIS; BACTERIOPHAGE; CONTROLLED STUDY; COVALENT BOND; CROHN DISEASE; FEMALE; IMMUNE DEFICIENCY; IMMUNIZATION; INFECTION SENSITIVITY; INFLAMMATION; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; TUBERCULOSIS; VIRUS LIKE AGENT;

EID: 34249809700     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.7450     Document Type: Article

References (38)

1. Slifman, N. R., S. K. Gershon, J. H. Lee, E. T. Edwards, and M. M. Braun. 2003. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum. 48: 319-324.
2. Wallis, R. S., M. Broder, J. Wong, and D. Beenhouwer. 2004. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39: 1254-1255.
3. Wallis, R. S., M. S. Broder, J. Y. Wong, M. E. Hanson, and D. O. Beenhouwer. 2004. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38: 1261-1265.
4. Jegerlehner, A., T. Storni, G. Lipowsky, M. Schmid, P. Pumpens, and M. F. Bachmann. 2002. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 32: 3305-3314.
5. Jegerlehner, A., A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, T. Bachi, T. Storni, G. Jennings, P. Pumpens, et al. 2002. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20: 3104-3112.
6. Bachmann, M F., U. H. Rohrer, T. M. Kundig, K. Burki, H. Hengartner, and R. M. Zinkernagel. 1993. The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
7. Spohn, G., K. Schwarz, P. Maurer, H. Illges, N. Rajasekaran, Y. Choi, G. T. Jennings, and M. F. Bachmann. 2005. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol. 175: 6211-6218.
8. Rohn, T. A., G. T. Jennings, M. Hernandez, P. Grest, M. Beck, Y. Zou, M. Kopf, and M. F. Bachmann. 2006. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36: 2857-2867.
9. Sonderegger, I., T. A. Rohn, M. O. Kurrer, G. Iezzi, Y. Zou, R. A. Kastelein, M. V. Bachmann, and M. Kopf. 2006. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 36: 2849-2856.
10. Ambuhl, P. M., A. C. Tissot, A. Fulurija, P. Maurer, J. Nussberger, R. Sabat, V. Nief, C. Schellekens, K. Sladko, K. Roubicek, et al. 2007. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens. 25: 63-72.
11. Marino, M. W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94: 8092-8098.
12. Botha, T., and B. Ryffel. 2002. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 107: 350-357.
13. Chackerian, B., D. R. Lowy, and J. T. Schiller. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108: 415-423.
14. Jones, E. Y., D. I. Stuart, and N. P. Walker. 1989. Structure of tumour necrosis factor. Nature 338: 225-228.
15. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon 7 receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 179: 1437-1444.
16. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467.
17. Bean, A. G., D. R. Roach, H. Briscoe, M. P. France, H. Korner, J. D. Sedgwick, and W. J. Britton. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162: 3504-3511.
18. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572.
19. Olleros, M. L., R. Guler, N. Corazza, D. Vesin, H. P. Eugster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia. 2002. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis Bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-α. J. Immunol. 168: 3394-3401.
20. Olleros, M. L., R. Guler, D. Vesin, R. Parapanov, G. Marchal, E. Martinez-Soria, N. Corazza, J. C. Pache, C. Mueller, and I. Garcia. 2005. Contribution of trans-membrane tumor necrosis factor to host defense against Mycobacterium bovis Bacillus Calmette-Guérin and Mycobacterium tuberculosis infections. Am. J. Pathol. 166: 1109-1120.
21. Saunders, B. M., S. Tran, S. Ruuls, J. D. Sedgwick, H. Briscoe, and W. J. Britton. 2005. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 174: 4852-4859.
22. Flynn, J. L., C. A. Scanga, K. E. Tanaka, and J. Chan. 1998. Effects of amino-guanidine on latent murine tuberculosis. J. Immunol. 160: 1796-1803.
23. Botha, T., and B. Ryffel. 2003. Reactivation of latent tuberculosis infection in TNF-deficient mice. J. Immunol. 171: 3110-3118.
24. Keane, J., S. Gershon, R. P. Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, I. N. Siegel, and M. M. Braun. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345: 1098-1104.
25. Lee, J. H., N. R. Slifman, S. K. Gershon, E. T. Edwards, W. D. Schwieterman, J. N. Siegel, R. P. Wise, S. L. Brown, J. N. Udall, Jr., and M. M. Braun. 2002. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum. 46: 2565-2570.
26. Wallis, R. S., M. Broder, J. Wong, A. Lee, and L. Hoq. 2005. Reactivation of latent granulomatous infections by infliximab. Clin. Infect. Dis. 41(Suppl 3): S194-S198.
27. Scallon, B., A. Cai, N. Solowski, A. Rosenberg, X. Y. Song, D. Shealy, and C. Wagner. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301: 418-426.
28. Musicki, K., H. Briscoe, S. Tran, W. J. Britton, and B. M. Saunders. 2006. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect. Immun. 74: 3180-3189.
29. Torres, D., L. Janot, V. F. Quesniaux, S. I. Grivennikov, I. Maillet, J. D. Sedgwick, B. Ryffel, and F. Erard. 2005. Membrane tumor necrosis factor confers partial protection to Listeria infection. Am. J. Pathol. 167: 1677-1687.
30. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184: 1397-1411.
31. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802.
32. Bachmann, M. F., and M. R. Dyer. 2004. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3: 81-88.
33. Alzani, R., A. Corti, L. Grazioli, E. Cozzi, P. Ghezzi, and F. Marcucci. 1993. Suramin induces deoligomerization of human tumor necrosis factor α. J. Biol. Chem. 268: 12526-12529.
34. He, M. M., A. S. Smith, J. D. Oslob, W. M. Flanagan, A. C. Braisted, A. Whitty, M. T. Cancilla, J. Wang, A. A. Lugovskoy, J. C. Yoburn, et al. 2005. Small-molecule inhibition of TNF-α. Science 310: 1022-1025.
35. Steed, P. M., M. G. Tansey, J. Zalevsky, E. A. Zhukovsky, J. R. Desjarlais, D. E. Szymkowski, C. Abbott, D. Carmichael, C. Chan, L. Cherry, et al. 2003. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301: 1895-1898.
36. Salzmann, M., and M. F. Bachmann. 1998. Estimation of maximal affinities between T-cell receptors and MHC/peptide complexes. Mol. Immunol. 35: 65-71.
37. Edwards, C. K., III, A. M. Bendele, L. I. Reznikov, G. Fantuzzi, E. S. Chlipala, L. Li, L. L. Moldawer, J. D. Mountz, Y. Y. Li, and C. A. Dinarello. 2006. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor α. Arthritis Rheum. 54: 2872-2885.
38. Georgopoulos, S., D. Plows, and G. Kollias. 1996. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 46: 86-97.